MOD3 Pharma

Executive Summary

MOD3 Pharma is a San Diego-based biotechnology company developing novel drug delivery technologies, with a focus on intranasal delivery and precision dosing systems. Founded in 2018, the company is currently at the pre-clinical stage, leveraging its proprietary platform to address respiratory and other therapeutic areas. The company's technology has been utilized in clinical studies for respiratory therapeutics, indicating potential for improved patient outcomes through more effective and less invasive drug administration. Despite limited public information, MOD3 Pharma's unique approach positions it to address unmet needs in drug delivery, particularly for conditions requiring rapid onset or targeted central nervous system effects. The company's mission centers on transforming innovative ideas into solutions that enhance patient care and everyday life, underscoring its patient-centric focus.

Upcoming Catalysts (preview)

• Q4 2026Completion of Key Preclinical Studies70% success
• Q2 2027Strategic Partnership or Licensing Deal40% success
• Q4 2027IND Filing for Lead Candidate30% success